GENMAB A/S |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,100 MXN | +3.92% |
|
-.--% | -4.52% |
| 04:14pm | Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' | MT |
| 02:28pm | Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 19.8B 2.89B 48.18B | Sales 2025 * | 23.62B 3.44B 57.48B | Capitalization | 133B 19.45B 325B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.68B 683M 11.4B | Net income 2025 * | 6.63B 967M 16.13B | EV / Sales 2024 * | 5.4 x |
| Net cash position 2024 * | 26.36B 3.84B 64.14B | Net cash position 2025 * | 33.63B 4.9B 81.85B | EV / Sales 2025 * | 4.22 x |
| P/E ratio 2024 * |
29.7
x | P/E ratio 2025 * |
21.3
x | Employees | 2,286 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab A/S
More recommendations
More press releases
More news
| 1 day | +3.92% | ||
| 3 months | -4.52% | ||
| 6 months | -4.26% | ||
| Current year | -4.52% |
Current year
4 907.84
5 100.00
1 year
4 907.845 375.45
3 years
4 907.849 759.80
5 years
4 907.849 759.80
10 years
4 907.849 759.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
| Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
2024-08-01
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
2,025
DKK
Average target price
2,470
DKK
Spread / Average Target
+21.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.45% | 111B | |
| +11.22% | 106B | |
| -12.49% | 22.24B | |
| +0.44% | 21.25B | |
| -37.85% | 18.52B | |
| -8.70% | 16.81B | |
| +37.63% | 12.54B | |
| -24.41% | 8.09B | |
| +315.58% | 7.99B |
- Stock Market
- Equities
- GMAB Stock
- GMAB N Stock
